The Role of Supplementary Immunization Activity Scheduling on Measles Incidence in Nigeria Kurt Frey April 20, 2017 IDM Disease Modeling Symposium Measles.

Slides:



Advertisements
Similar presentations
Progress in Measles Control in the African Region Annual Measles Partnership meeting Feb 2007 Washington DC.
Advertisements

Global Measles and Rubella Strategic Plan
Measles elimination in the African Region- Regional updates
Measles Outbreaks in Southern Africa in 2010 Presentation to the MI 10 th annual meeting Sept 2011 B Masresha WHO AFRO.
“Concepts in evaluation of vaccination programs in low income countries" Jagrati Jani Section for International Health Department of Community Medicine.
1 Dr. Azhar Abid Raza Washington Sept 2011 Measles elimination in Pakistan.
How can Modeling Help in Emerging Epidemics? John Grefenstette, PhD Public Health Dynamics Lab Health Policy & Management Pitt Public Health Dec 5, 2014.
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
Monitoring & Evaluation for Routine Immunization: Data For Action
The Cape Verde experience with rubella outbreak & lessons from introducing rubella vaccines MoH Cape Verde ARCI meeting Dar es Salaam, Tanzania Dec 2012.
A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,
Comparing Rubella Vaccination Strategies in China Linda Q. Gao North Central College Herbert Hethcote The University of Iowa May 18, 2004 DIMACS.
Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.
How does mass immunisation affect disease incidence? Niels G Becker (with help from Peter Caley ) National Centre for Epidemiology and Population Health.
Reaching the 2010 Measles Mortality Reduction Goal-can SEARO get there? Meeting of the Partners for Measles Advocacy Washington DC, September 2008.
Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.
1 1 Measles elimination and rubella control in the SEA Region- a brief Update 12 th Annual Meeting of the Measles Rubella Initiative (MRI) September,
Current Status of Immunization Service Delivery in Africa Mary Harvey AFR/SD/HRD SOTA/PHN Meeting June 13, 2002.
Showcase /06/2005 Towards Computational Epidemiology Using Stochastic Cellular Automata in Modeling Spread of Diseases Sangeeta Venkatachalam, Armin.
Funding Update: 2013 – 2015 September 10,
MEASLES AND RUBELLA INITIATIVE Presentation by : Sylvia Khamati. Health Advisor Kenya Red Cross Society “Story from the Field” 15 th September 2015 American.
Measles pre-elimination in the African Region. Presentation to the MI 10 th annual meeting Sept 2011 B Masresha WHO AFRO.
Global Overview of Measles & Rubella 11 th Annual Meeting The Measles Initiative Washington, DC th September, 2012.
1 |1 | Measles pre-elimination and resurgence in the African region Balcha Masresha IVD AFRO Global Measles Management Meeting Geneva March 2011.
Situation overview and Meeting Objectives The Middle East Polio Outbreak Phase II Review.
Research and Methodology
Update on Progress toward Measles Situation in EMR September 2008 Dr B. Naouri VPI/DCD/EMRO.
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
Sustaining the gains and reaching milestones on the way towards elimination of measles and rubella 15 September 2015 Dr Peter Strebel, WHO, IVB/EPI.
Measles and Rubella Initiative Financial Resource Requirements for Measles and Rubella Annual Partners Meeting, September
Session 7: Planning for Evaluation. Session Overview Key definitions:  monitoring  evaluation Process monitoring and process evaluation Outcome monitoring.
New Vaccine Introduction ‘MR vaccine introduction in Kenya’
Impact of Childhood Hepatitis A Vaccination: New York City Vikki Papadouka, PhD, MPH Jane R. Zucker, MD, MSc Sharon Balter, MD Vasudha Reddy, MPH Kristen.
Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.
Rubella Surveillance and Control in Low-Resource Settings: Limitations, Biases, and Potential for Strengthening Amy Winter, PhD Candidate, Princeton University.
04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.
Global Measles and Rubella: Highlights, Priorities and Critical Issues
Measles Rubella Meeting
Mortality: Model Life Tables
Sangeeta Venkatachalam, Armin R. Mikler
Global Overview of Measles
S CONCLUSION Seasonal Variation in the Occurrence of Thrombotic
53 Member States >900 million inhabitants WHO European Region
Vaccine Efficacy, Effectiveness and Impact
Challenges and opportunities associated with the new SIA coverage survey guidelines, and practical issues related to implementing these guidelines Accelerating.
Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-matched Controls: A Population-Based Study in Metropolitan Atlanta F.
From: Cholera Epidemic in Haiti, 2010: Using a Transmission Model to Explain Spatial Spread of Disease and Identify Optimal Control Interventions Ann Intern.
RAcE Niger Final Evaluation Results
مراقبت بيماريهاي بثوري تب دار باهدف حذف سرخك و سرخجه
23 November, 2018 Update on measles & rubella surveillance in the WHO African Region – progress and challenges Dr Richard Luce WHO/IST-Central 5th African.
African Region- priorities to reach the 2020 measles elimination goal.
Experience with the measles outbreak response fund
Epidemiological Modeling to Guide Efficacy Study Design Evaluating Vaccines to Prevent Emerging Diseases An Vandebosch, PhD Joint Statistical meetings,
World Health Organization
Plasma 25-Hydroxyvitamin D and Risk of Non-Melanoma and Melanoma Skin Cancer: A Prospective Cohort Study  Shoaib Afzal, Børge G. Nordestgaard, Stig E.
Measures of Disease Occurrence
by Michael J. Mina, C. Jessica E. Metcalf, Rik L. de Swart, A. D. M. E
Anatomy of an Epidemic.
Provincial Measles Immunization Catch-Up Program
Epidemiological Measurements of health
Volume 393, Issue 10178, Pages (March 2019)
Influenza Vaccine Program Effectiveness in the United States
State of Measles Initiative Financing Partners for Measles Advocacy Meeting Washington, D.C. September 22, 2008 Andrea Gay.
Epidemiological Terms
Maintaining Elimination in an Environment of Persistent Importation
Trends for ECDC measles and rubella monitoring,
Institute for Disease Modelling Symposium
Research Update: The HPV Vaccines
Introduction to OpenMalaria
Akiko C. Kimura, MD Jeffrey Higa, MPH Christine Nguyen, MPH
Presentation transcript:

The Role of Supplementary Immunization Activity Scheduling on Measles Incidence in Nigeria Kurt Frey April 20, 2017 IDM Disease Modeling Symposium Measles 2

Overview Introduction to Measles Burden in Nigeria Results from Spatially Homogeneous Simulations of Nigeria Incidence, age-at-infection; inputs to EMOD simulation software Differences in Pre- and Post- Supplementary Immunization Eras SIAs have created a regularity in measles incidence Consequences of SIA Scheduling Opportunities for burden reduction through timing interventions

Measles in Nigeria 2007-2016 Major groupings indicate DHS regions with reported measles incidence per total population. Total Reported Cases: Northwest: 55% Northeast: 25% Elsewhere: 20% Estimated 2015 Population: Northwest: 25% (48M) Northeast: 14% (26M) Elsewhere: 61% (115M)

Spatially Homogeneous Simulations Calculated and Observed Incidence Case-based incidence reports of measles have been used to estimate measles infectivity-related descriptors in IDM’s Epidemiological Modeling software (EMOD).

EMOD Specifications Simulations were focused entirely on the under-five cohort; this cohort encompasses 17% of the total population, and 80% of the total measles burden. This iteration of the model represents the entire country as a single, well-mixed population, using overall averages for demographic parameters. ● Raw birthrate of 40/1000; seasonal birthrate forcing of around 30% ● Age dependent non-disease mortality (i.e., neo-natal, infant, etc.) Disease descriptors: Maternal immunity: ● 10 ± 2 day incubation period ● 8 ± 2 day infectious period ● No disease-specific deaths Vaccination immunity results from a 40% rate of routine immunization, and SIA campaign schedules / coverages as reported by the WHO for the period 2005 – 2015. Age (Month) 0 - 3 5 7 9 100% 51% 26% 13%

SIA Era 2006-Present Regular follow-up campaigns of supplementary immunizations have created a corresponding regularity to the intensity of measles outbreaks in Nigeria. Outbreaks in the current era can either be self-limited (from a depletion of susceptibles), or seasonally-limited (from an annual decrease in infectivity). Note: Infectivity = Disease * Mixing

Scheduling SIAs Heuristics suggest scheduling interventions several months prior to peak infectivity. Logistic challenges sometimes result in delays (e.g., 2010 and 2015).

Scheduling SIAs With a 2-year time window, targeting an SIA for October or November provides the greatest burden reduction.

Next Steps Evaluate the time horizon needed to establish an equilibrium for biennial SIAs Explore the trade-offs involved with annual SIAs Contrast with expanded age-range SIAs Improve spatial resolution Examine subnational regions of Nigeria independently Investigate heterogeneous SIA scheduling

Questions

Figure

Figure Bimonthly Reported Measles Incidence in Nigeria 6000 Observed Simulations 4000 2000 2009 2010 2011 2012 2013 2014 2015

Figure Age-at-Infection (<5yr Cohort) 0.4 Mean Value Simulations: 1.8 0.3 Observed: 2.0 Fraction 0.2 0.1 0.0 1 2 3 4 5 Age (yr)

Figure Observed Reported Annual Incidence 1990 1995 2000 2005 2010 300k 200k Observed Reported Annual Incidence 100k 1990 1995 2000 2005 2010 2015 120k 80k Simulated Reported Monthly Incidence 40k

Observed Reported Monthly Incidence Figure 20k National SIA National SIA Observed Reported Monthly Incidence 10k 2009 2010 2011 2012 2013 2014

Figure National SIA Implementation 2010 2011 2012 Feb Base Case 2011 5k Feb Base Case 2011 Jan 4k Dec 2010 Nov 3k Oct 2k Sept 1k 2010 2011 2012

Figure Simulated Reported Cumulative Incidence 2011-2012 20k Base Case 16k 12k Simulated Reported Cumulative Incidence 2011-2012 8k 4k Sept Oct Nov Dec Jan 2010 2011 Time of SIA Implementation